USP1 and breast carcinoma: For instance, KSQ-4279 has been recognized as a promising therapy for overcoming poly(ADP-ribose) polymerase (PARP) inhibitor resistance in breast cancer susceptibility gene (BRCA)-mutant tumors, while ML323 demonstrates effectiveness in suppressing ovarian cancer cell proliferation by targeting USP1-regulated cell cycles [16].